Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Voyager Therapeutics (VYGR) FCF Margin: 2015-2025

Historic FCF Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to -233.25%.

  • Voyager Therapeutics' FCF Margin fell 11864.00% to -233.25% in Q3 2025 from the same period last year, while for Sep 2025 it was -378.79%, marking a year-over-year decrease of 36130.00%. This contributed to the annual value of -23.54% for FY2024, which is 5340.00% down from last year.
  • Voyager Therapeutics' FCF Margin amounted to -233.25% in Q3 2025, which was up 64.71% from -660.88% recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' FCF Margin registered a high of 5,197.26% during Q1 2022, and its lowest value of -2,743.96% during Q2 2022.
  • Over the past 3 years, Voyager Therapeutics' median FCF Margin value was -114.60% (recorded in 2024), while the average stood at -192.36%.
  • In the last 5 years, Voyager Therapeutics' FCF Margin spiked by 553,058bps in 2022 and then crashed by 511,549bps in 2023.
  • Over the past 5 years, Voyager Therapeutics' FCF Margin (Quarterly) stood at 38.64% in 2021, then spiked by 81,149bps to 850.13% in 2022, then plummeted by 87,735bps to -27.22% in 2023, then tumbled by 20,668bps to -233.90% in 2024, then slumped by 11,864bps to -233.25% in 2025.
  • Its FCF Margin was -233.25% in Q3 2025, compared to -660.88% in Q2 2025 and -593.12% in Q1 2025.